Figure 2.
(A) Number per 0.75mm2 and (B) percent area covered by amyloid plaques in the cortex and the hippocampus of Tg19959 mice (Tg) treated with (Apo) or without (Veh) apocynin. Apocynin administration did not reduce amyloid deposition in Tg19959 mice. Cortical and hippocampal levels of 6% SDS-soluble Aβ42 (C) and Aβ40 (D) assessed by ELISA (data normalized by Tg19959 mice fed vehicle). There was a trend towards an increase of Aβ40 level in the cortex of Tg19959 mice treated with apocynin compared to vehicle (Fisher; p=0.12). (E) Western blotting of hyperphosphorylated tau and α-tubulin in the cortex and the hippocampus of Tg19959 mice (Tg) treated with (Apo) or without (Veh) apocynin. (F) Ratio of hyperphosphorylated tau to α-tubulin normalized by Tg19959 mice fed vehicle. There was a trend towards a decrease of hyperphosphorylated tau level in the hippocampus of Tg19959 mice treated with apocynin compared to vehicle (Fisher; p=0.15). (G) Percent area covered by activated microglia in the cortex and the hippocampus of Tg19959 mice (Tg) treated with (Apo) or without (Veh) apocynin. Apocynin administration did not change microglial activation in Tg19959 mice. All data were expressed as means ± standard errors.